Novogene Co., Ltd. (SHA:688315)
14.18
-0.29 (-2.00%)
Apr 21, 2026, 3:00 PM CST
Novogene Revenue
Novogene had revenue of 556.43M CNY in the quarter ending March 31, 2026, with 10.84% growth. This brings the company's revenue in the last twelve months to 2.26B, up 5.56% year-over-year. In the year 2025, Novogene had annual revenue of 2.21B with 4.66% growth.
Revenue (ttm)
2.26B
Revenue Growth
+5.56%
P/S Ratio
2.54
Revenue / Employee
1.03M
Employees
2,190
Market Cap
5.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.21B | 98.32M | 4.66% |
| Dec 31, 2024 | 2.11B | 109.21M | 5.45% |
| Dec 31, 2023 | 2.00B | 76.47M | 3.97% |
| Dec 31, 2022 | 1.93B | 59.24M | 3.17% |
| Dec 31, 2021 | 1.87B | 376.37M | 25.26% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Wuhan Hvsen Biotechnology | 1.68B |
| Kexing Biopharm | 1.54B |
| Shenzhen Weiguang Biological Products | 1.14B |
| ChemPartner PharmaTech | 1.07B |
| Beijing Konruns Pharmaceutical | 871.31M |
| R&G PharmaStudies | 851.01M |
| PharmaResources (Shanghai) | 667.47M |
| Lifecome Biochemistry | 502.95M |